Last $67.70 USD
Change Today +0.76 / 1.14%
Volume 6.6M
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ivan P. Gergel M.D.

Chief Medical Officer and Senior Vice President of Drug Development, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 39 board members in 3 different organizations across 6 different industries.

See Board Relationships
53--

Background*

Dr. Ivan P. Gergel, M.D., serves as the Chief Medical Officer and Senior Vice President of Drug Development at Nektar Therapeutics since May 19, 2014. Dr. Gergel served as the Chief Scientific Officer and Executive Vice President of Research & Development at Endo Health Solutions Inc. from April 2008 to March 31, 2014. He has been an Executive Vice President of Research & Development of Endo Pharmaceuticals Solutions Inc. since April 2008. He has full responsibility ...

Read Full Background

Corporate Headquarters*

Glandore Business Centres
Dublin, Co. Dublin 2

Ireland

Phone: 353 1 699 4700
Fax: --

Board Members Memberships*

Director
2009-N/A
Executive Vice President of Research & Development
2010-Present
Director
2010-Present
Director

Education*

MBA
University of Pennsylvania - The Wharton School
MD
Royal Free and University College Medical School

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $67.70 USD +0.76

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Senior Vice President of Finance, Treasurer and Director
Theravance Inc.
$515.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$590.6K
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
--
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.